Disease | lung cancer |
Phenotype | C0007134|renal cell carcinoma |
Sentences | 2 |
PubMedID- 23937707 | Pazopanib has been shown to have significant clinical benefit in several phase ii and iii studies in a wide variety of malignancies, including soft tissue sarcoma, thyroid cancer, ovarian cancer, non-small cell lung cancer [19-23], and in patients with metastatic renal cell carcinoma (rcc) [19,24]. |
PubMedID- 22830255 | A substantial increase in neto2 mrna level was detected in 90% clear-cell renal cell carcinomas, 70% of non-small cell lung cancers, and 50% of papillary renal cancers by real-time pcr. |
Page: 1